Dehydroabietic acid alleviates high fat diet-induced insulin resistance and hepatic steatosis through dual activation of PPAR-γ and PPAR-α. by Xie, Z et al.
Contents lists available at ScienceDirect
Biomedicine & Pharmacotherapy
journal homepage: www.elsevier.com/locate/biopha
Dehydroabietic acid alleviates high fat diet-induced insulin resistance and
hepatic steatosis through dual activation of PPAR-γ and PPAR-α
Zhishen Xiea, Gai Gaoa, Hui Wanga, Erwen Lia, Yong Yuana, Jiangyan Xua,*, Zhenqiang Zhanga,*,
Pan Wanga, Yu Fua, Huahui Zenga, Junying Songa, Christian Hölschera, Hui Chenb
a Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, 450046, China
b School of Life Sciences, Faculty of Science, University of Technology Sydney, PO Box 123, Broadway, NSW, 2007, Australia







A B S T R A C T
Dual-PPAR-α/γ agonist has the dual potentials to improve insulin resistance (IR) and hepatic steatosis associated
with obesity. This study aimed to investigate whether dehydroabietic acid (DA), a naturally occurred compound,
can bind to and activate both PPAR-γ and PPAR-α to ameliorate IR and hepatic steatosis in high-fat diet (HFD)-
fed mice.. We found that DA formed stable hydrogen bonds with the ligand-binding domains of PPAR-γ and
PPAR-α. DA treatment also promoted 3T3-L1 differentiation via PPAR-γ activation, and mitochondrial oxygen
consumption in HL7702 cells via PPAR-α activation. In HFD-fed mice, DA treatment alleviated glucose intol-
erance and IR, and reduced hepatic steatosis, liver injury markers (ALT, AST), and lipid accumulation, and
promoted mRNA expression of PPAR-γ and PPAR-α signaling elements involved in IR and lipid metabolism in
vivo and in vitro, and inhibited mRNA expression of pro-inflammatory factors. Therefore, DA is a dual-PPAR-α/γ
and PPAR-γ partial agonist, which can attenuate IR and hepatic steatosis induced by HFD-consumption in mice.
1. Introduction
Diabetes mellitus (DM) is a global disease [1,2], 1 in 10 people are
living with diabetes, according to the international diabetes federation’s
report. Insulin resistance (IR) is the major feature of type 2 diabetes
(T2DM), the most common type of diabetes, accounting for around 90
% of all DM cases. T2DM is a chronic metabolic disease, usually asso-
ciated with obesity, hyperlipidemia, hepatic steatosis, etc [3–5].
Peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ
belong to the nuclear receptor superfamily [6,7]. PPAR-γ regulates
adipogenesis and insulin sensitivity [8], whose selective agonists
(thiazolidinediones (TZDs), such as thiazolidinediones and rosiglita-
zone (RSG)) have been used as 2nd line anti-type 2 diabetic drugs for
decades. These two drugs clinically used as PPAR-γ agonists can re-
model adipose tissue resulting in adipocyte hypertrophy and hyper-
plasia, which is used as a mechanism to improve systemic insulin sen-
sitivity [9,10]. On the other hand, such newly differentiated adipocytes
are insulin sensitive which facilitates postprandial glucose uptake and
conversion into triglycerides (TG) for long-term storage. As such,
weight gain is a significant side effect of thiazolidinediones and RSG, in
addition to liver toxicity which requires regular surveillance of liver
function. Troglitazone, strongly activates PPAR-γ, has been
discontinued in clinical use, because of undesirable clinical side effects
such as weight gain, liver damage and osteoporosis [11]. PPARα is
widely expressed and serves to activate FAO pathways in many tissues
and cells including the intestine, vascular endothelium, smooth muscle
and immune cells such as monocytes, macrophages and lymphocytes
and the liver controls several key genes [12], involved in lipid home-
ostasis [13,14], including lipolysis and mitochondrial fatty acid β-oxi-
dation [15,16], permit efficient use of mobilized lipids and decrease
secretion of triglycerides (TGs) from the liver and promote TG clearance
from plasma, and thereby also reduce atherogenic lipoprotein particles.
It was this activity that prompted therapeutic development to reduce
cardiovascular risk, fat liver in patients with raised plasma lipids [13]..
Metabolic disorders such as diabetes, atherosclerosis, hyperlipidemia
and obesity, rarely occur in isolation, but usually arise in the same
individuals. Large numerous studies have shown that the development
of PPAR-α/γ dual agonists or PPAR-γ partial agonists are developed to
increase insulin sensitivity and alleviate hepatic steatosis is a promising
approach [17–19].
Dehydroabietic acid (DA), is a derivative of abietic acid (AA) which
is the primary irritant in pinewood [20]. DA and AA also derive from
rosin, which is often used for plucking duck feather. Therefore, DA was
found in raw and cooked ducks [21].DA and AA have been shown to
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have anti-aging [22], anti-inflammatory [23–25], anti-bacterial [26],
and anti-cancer effects [27,28]. In the genetic obese diabetic KK-Ay
mice, DA supplement in the chow has been shown to effectively reduce
fasting blood glucose levels [29]. DA increased expression of PPAR-γ
and-α [23] and stimulated insulin dependent glucose uptake into 3T3-
L1 adipocyte in vitro [30]. It is reasonable to assume that DA may
overcome such side effects of TZDs due to it proposes dual PPAR-γ/α
action. In addition, the anti-inflammatory effects via inhibiting NF-κB
signaling pathway elements are commonly proposed mechanisms in
improving systemic insulin sensitivity, as inflammation plays a key role
in compromising insulin signaling cascade [24,29], in addition to in-
creasing adiponectin and glucose uptake by Glut-4 [29]. It was also
shown that the DA treatment suppressed the production of monocyte
chemoattractant protein-1 (MCP-1) and tumor necrosis factor-α (TNF-
α) (proinflammatory cytokines) [29], inhibited NF-κB signaling
pathway [24], increased adiponectin expression (an anti-inflammatory
cytokine) [29]. Both in vitro and in vivo studies identified PPAR-γ/α
influences on both acute and chronic inflammatory processes [13,31].
Taken together, it is reasonable to assume that DA could alleviate IR
and hepatic steatosis via activate PPAR-γ/α and overcome such side
effects of TZDs.
In this study, we found that DA is a dual-PPAR-α/γ and PPAR-γ
partial agonist and firstly provided visual evidence of how DA and AA
bind to PPAR-γ and PPAR-α. The effects on metabolic phenotypes of IR
and hepatic steatosis were verified in high fat diet (HFD)-induced obese
mice, an animal model more consistent with human diabetes mellitus.
DA promotes fatty acid β-oxidation, prevents IR and hepatic steatosis
which maybe depend on PPAR-γ and PPAR-α activation. As expected,
DA overcome PPAR-γ side effects such as weight gain and fat liver.
2. Materials and methods
2.1. Reagents
Dulbecco’s modified Eagle’s medium (DMEM, Gibco, US); Fetal
bovine serum (FBS; Gibco, US); Penicillin-streptomycin solution
(Solarbio, China); HEK293 T, 3T3-L1 and HL7702 cell (ATCC, US);
Dehydroabietic acid (DA), abietic acid (AA), Rosiglitazone (RSG); Oleic
acid, Dexamethasone (Dex), Oil red O, GW9662 (Aladdin, China);
Insulin (Ins, MedChemExpress, US); WY14643 (Selleck Chemicals, US);
GW6471 (Glpbio, US); Nile red (Macklin, China), 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT, Solarbio,
China); Sodium carboxymethylcellulose, Dimethyl sulfoxide (DMSO,
Macklin, China); D12492 (Jiangsu Xietong Pharmaceutical Bio-en-
gineering Co., Ltd., China).
2.2. PPAR-γ and PPAR-α binding assays
For the PPAR-γ or PPAR-γ -α activity assay, plasmid pSG5-PPAR-γ
or PPAR-γ -α and the PPAR promoter–reporter vector J3-TKLuc were
used as previously described [32]. For PPAR-γ-LBD or PPAR-α-LBD
assay, plasmid GAL4-PPARγ-LBD or GAL4-PPAR-α-LBD fusion protein
and a pGL4.35 reporter were used [33].
HEK293 T cells were seeded at a density of 2 × 104 cells per well
into 96-well plates for 18 h and transfected over a 6 h period with 100
ng plasmid expressed target genes and 10 ng of β-galactosidase reporter
to normalize transfection efficiencies using lip2000 transfection re-
agents. Then, they were treated with DA or AA (2.5–50 μM) or RSG
(0.0001–50 μM) for 24 h. The luciferase was detected using the luci-
ferase reporter assay kit (Promega, US).
2.3. Cell culture
Pre-adipocyte 3T3-L1 and human liver cell HL7702 were main-
tained in DMEM high glucose medium containing 10 % FBS and 1%
penicillin-streptomycin solution and cultured at 37 °C in 5% CO2
incubator (Thermofisher). Cell viability was tested in 3T3-L1 and
HL7702 cells with various doses of DA and AA using MTT assay.
For 3T3-L1 cell differentiation, cells were seeded into 6-well plates
to full confluence for 2 days, and then induced by completed medium
containing 10 μg/mL insulin, 1 μM dexamethasone. After 2 days of
induction, the medium was replaced with a maintenance medium
(completed medium including 10 μg/mL insulin) as well as different
compounds (20 μM RSG, or 2.5, 5, 10, 15 μM DA) The last incubation
lasted for 4 days before Oil Red O staining as previously reported [34].
For quantification, oil red O was extracted by isopropanol for 20 min. at
room temperature and then transferred it to a 96-well plate, and
measured the absorbance value at 500 nm.
To investigate the effects on the expression of PPAR-γ target genes,
3T3-L1 cells were collected at 0th, 4th and 6th day during the differ-
entiation with test compound for Glut-4, Cyp4a10 and Scd-1 mRNA
measurement.
2.4. Intracellular lipid analysis and oxygen consumption of HL7702 cells
For intracellular lipid analysis, HL7702 cells were plated at 2 × 105
cells per well in 6-well plates and treated with different compounds (10
μM WY14643 (PPAR-α agonist)), or 2.5, 5, 10 μM DA or 10 μM DA +
10 μMGW6471 (PPARα antagonist) together with 0.6 mM oleic acid for
24 h. The cells were stained with nile red and observed by fluorescence
microscopy and lipid drops observed by transmission electron micro-
scope (JEM-1400; JEOL Ltd., Tokyo, Japan) [35].
Oxygen consumption rate (OCR) was measured by Seahorse bioa-
nalyzer as previously described. Briefly, HL7702 cells were seeded at a
density of 2.5 × 104 cells per well in a collagen coated XFe96 cell
culture microplate, with or without the test compounds (10 μM
WY14643, or 2.5, 5, 10 μM DA or 10 μM DA + 10 μM GW6471) for 23
h prior to the assay. Oligomycin (1 μM), FCCP (1 μM) and Rotenone and
Antimycin A (1 μM) were administered during the assay according to
manufacturer’s instructions.
2.5. Animal experiments
All animal protocols were approved by the State of Animal Ethics
Committee of Henan University of Chinese Medicine
(DWLL201912032). The mice were kept with constant temperature
(22±2 °C) and humidity (55 %) with a 12 h light/dark cycle with
water and food ad libitum. After one week of adaptation to the en-
vironment, male C57BL/6 J mice (8 weeks, Beijing Vital River
Laboratory Animal Technology Co., Ltd., China) were fed normal chow
diet (NCD, 10 % energy from fat) and high-fat diet (HFD, 60 % energy
from fat, 20 % energy from protein, Cat. D12492, Jiangsu Xietong
Pharmaceutical Bio-engineering Co., Ltd., China) for 12 weeks [36].
Then, the HFD mice were randomly divided into 4 groups and gavaged
with rosiglitazone (RSG, 4 mg/kg/d), low dose of DA (DA-L, 10 mg/kg/
d), high dose of DA (DA-H, 20 mg/kg/d) [29], and saline respectively
for 9 weeks (n = 8–12). NCD group received 0.5 % CMC-Na.
After 7 weeks of treatment, an insulin tolerance test (ITT) was
performed following 6 h fasting. After insulin injection (1 IU/kg, i.p.),
blood was taken from the tail vein at 0, 30, 60, 90, 120, 150 min. After
4 days, oral glucose tolerance test (OGTT) was carried out following 12
h fasting. After glucose administration (2 g/kg, gavage), blood was
taken from the tail vein at 0, 15, 30, 60, 90, 120 min post gavage. The
area under the curve (AUC) was calculated for each mouse (GraphPad
Prism 7.0).
At the endpoint, liver, interscapular brown fat, and epididymal fat
pads were fixed in 4% paraformaldehyde for immunohistochemistry
staining as previously described [37], or snap frozen in liquid nitrogen
and store at −80 °C for mRNA measurement.
Z. Xie, et al. Biomedicine & Pharmacotherapy 127 (2020) 110155
2
2.6. Bioassays
Plasma aspartate aminotransferase (AST), alanine aminotransferase
(ALT), triglyceride (TG), total cholesterol (TC), low-density lipoprotein
cholesterol (LDL-c) and high-density lipoprotein cholesterol (HDL-c)
were measured in the blood by the automatic biochemical analyzer
(OLYMPUS AU400, Japan).
2.7. Histological and immunohistochemical analysis
Fresh liver and fat sections were fixed with 4% paraformaldehyde,
embedded in paraffin, and cut into 4 μm sections for hematoxylin-eosin
(H&E) staining. Images were obtained with an Olympus microscope-
camera system (Tokyo, Japan). Adipocyte cell size was measured in H&
E stained tissues [38] and quantified by Image J software (Image J,
National Institutes of Health, MD, USA). Immunohistochemical staining
was performed using monoclonal anti-PPAR-α (1 : 200, Servicebio), ati-
ACADM antibody (1 : 200, Servicebio), mouse anti-UCP-1 (1 : 200,
ABclonal) and anti-CPT1α (1 : 200, ABclonal) as previously published
[37,39] and quantification by ImageJ (Media Cybernetics, Inc, USA).
Clinical nonalcoholic steatohepatitis (NASH) Activity Score (NAS) was
used to assess the liver as previously described [40].
2.8. Quantitative real-time PCR
Total RNAs were isolated using trizol (Vazyme, China). Equal
amounts of RNA from 8 mice were pooled [41,42] for cDNA synthesis
using a cDNA synthesis kit (Beyotime, China). Quantitative real-time
PCR was performed using SYBR green primers (sequences in Supple-
mentary Table 1, ABI 7500), GAPDH was used as a housekeeping gene,
and the expression of the target genes was calculated according to the
formula 2−△△Ct.
2.9. Statistical analysis
Data were expressed as the mean± standard error of the mean
(SEM). Comparisons between two groups were assessed using Student’s
t-test, and comparisons for more than 2 groups were analyzed using
one-way analysis of variance (ANOVA) followed by Dunnett’s post hoc
tests (GraphPad Prism 7.0). p<0.05 was considered statistically sig-
nificant.
3. Results
3.1. DA is a dual-PPAR-α/γ and PPAR-γ partial agonist
Firstly, we investigated the effect of DA on the activity of PPAR-γ
and PPAR-α. As shown in Fig. 1A, DA induced more than 3 times ac-
tivation of PPAR-γ compared with AA, however only to ¼ of which RSG
has achieved at the same dose. DA also induced∼5 times the activity of
PPAR-γ (LBD) than that of AA (Fig. 1B). Molecular docking results
suggest that DA and AA binding to the LBD of PPAR-γ at ARG280 by
forming 3 and 2 hydrogen bonds, respectively. DA showed lower
binding energy than AA (Fig. 1C, D). More importantly, DA also in-
duced 1.4 times more activities of PPAR-α than AA (Fig. 1E). The PPAR-
α-LBD activation was also ∼1.8 times higher with DA than AA
(Fig. 1F). DA formed hydrogen bonds with PPAR-α-LBD at ARG465 and
LYS448, while AA at LYS448 and LYS449. DA also had lower binding
energy with PPAR-α-LBD than AA (Fig. 1G, H) Taken together, DA is a
natural PPAR-γ partial agonist and also a dua-PPAR-α/γ agonist.
3.2. DA promotes pre-adipocytes differentiation and PPAR-γ activities in
adipocytes
In liver cells line HL7702 and pre-adipocytes 3T3-L1, DA treatment
(100 μM) only marginally decreased cell viability, and DA showed less
toxicity than AA (Supl Fig S1A and B). Therefore, DA was used for the
rest in vitro and in vivo studies.
Promoting pre-adipocytes differentiation is an important me-
chanism for how RSG improves glycemic control. We compared the
effects of DA and RSG on pre-adipocyte 3T3-L1 differentiation. As
shown in Fig. 2A, DA promoted 3T3-L1 adipocyte differentiation in a
dose-dependent manner. Oil red O staining also showed a dose-de-
pendent effect of DA to increase lipid deposition in the adipocytes with
the strongest effect at 15 μM (F (5, 42) = 388.6, p< 0.001, Fig. 2B).
However, 10 μM was chosen for later in vitro studies based on the cell
viability assays (Supl Fig. S1).
mRNA expression of PPAR-γ target genes involved in pre-adipocytes
differentiation Glut-4, Scd-1 and Cyp4a10, showed a time-dependent
increase during the differentiation. DA exerted similar effect as RSG to
increase Glut-4 (Fig. 2C) and Cyp4a10 expression (Fig. 2D), however
less effect than RSG on Scd-1 (F (2, 6) = 16.92, p = 0.0034, Fig. 2E) on
day 6 of the differentiation.
In differentiated adipocytes, DA at 10 μM exerted similar effects as
RSG at 20 μM to upregulate mRNA expression of known PPAR-γ target
genes, including those involved in adipogenesis (CAAT/enhancer
binding protein β (CEBPB), fatty acid binding protein 4 (FABP4), cor-
tisone reductase 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1),
mitochondrial carbohydrate metabolic marker Pyruvate
Dehydrogenase Lipoamide Kinase Isozyme 4 (PDK4)), while the effect
on the lipid metabolic regulator phosphodiesterase 3 (PED3B) was
stronger than the RSG (F (2, 6) = 31.59, p = 0.0007, Fig. 3A). DA
treatment increased transcription of the insulin sensing adiponectin (F
(2, 6) = 31.34, p = 0.0007; p<0.001 vs. DMSO, Fig. 3B), and lipid
metabolic marker angiopoietin-like protein 4 (ANGPTL4, F (2, 6) =
114.6, p< 0.0001, Fig. 3C), at much higher levels than RSG treatment
(p< 0.001, DA10 vs. RSG). Furthermore, DA had similar effect to RSG
to increase the mRNA expression of leptin (F (2, 6) = 7.806, p =
0.0214, Fig. 3D) and the regulator of lipid and glucose metabolism,
fibroblast growth factor 21 (FGF21, F (2, 6) = 162.8, p< 0.0001,
Fig. 3E), and reduce the mRNA expression of inflammatory regulator
angiopoietin-like protein 2 (ANGPTL2, F (2, 6) = 31.51, p = 0.0007,
Fig. 3F) and retinoic acid receptor responder 2 (PARRES2, F (2, 6) =
5.86, p = 0.0388, Fig. 3G) which encodes the adipokine Chemerin
involved in adipocyte differentiation and lipolysis.
3.3. DA decreases lipid accumulation and promotes mitochondrial function
via PPAR-α in HL7702 cells
Oleic acid was used to induce lipid accumulation in HL7702 cells.
Nile red binds to lipids and gives off orange fluorescence, which is often
used to analyze cell lipid contents. As expected, oleic acid increased
lipid accumulation in the HL7702 cells, which was prevented by both
DA and PPAR-α agonist WY14643 (Fig. 4A, C; F (4, 25) = 22.93,
p< 0.0001; both p<0.001 vs. Oleic acid). However, GW6471, a se-
lective PPAR-α antagonist, blocked the effect of DA on Oleic acid –
induced lipid accumulation, which suggested this effect of DA is PPAR-
α mediated (Fig. 4A, C). This was further confirmed by the measure-
ment of the areas of the lipid droplets by electron microscope (F (4, 25)
= 36.97; p< 0.0001, Fig. 4B, D).
Using a seahorse assay, mitochondrial oxygen consumption rates
(OCR) were measured in HL7702 cells. WY14643 had the strongest
effect to enhance mitochondrial activities including ATP synthesis,
followed by DA (Fig. 4E, F). However, GW6471 only partially blocked
this effect of DA, suggesting DA also works on other pathways to reg-
ulate mitochondrial metabolism (Fig. 4E, F). As shown in Fig. 4G, DA
upregulated the expression of classical PPAR-α target genes mostly at
10 μM, including those genes involved in fatty acid β-oxidation (car-
nitine palmitoyl transferase 1α (CPT-1α, F (3, 8) = 81.52, p<0.0001),
acyl-CoA dehydrogenase, long chain (ACDAL, F (3, 8) = 31.54,
p< 0.0001) and uncoupling protein-3 (UCP-3,F (3, 8) = 71.75,
p< 0.0001). It needs to be noted that the effect of DA on gene
Z. Xie, et al. Biomedicine & Pharmacotherapy 127 (2020) 110155
3
expression is not always comparable to PPAR-α agonist WY14643,
stronger on some genes whereas weaker on the others than WY14643,
suggesting that other pathways may be activated by DA.
3.4. DA alleviates HFD-induced glucose intolerance and insulin resistance in
vivo
As shown in Fig. 5A (F (4, 35) = 20.47, p< 0.0001), after 21 weeks
of HFD consumption, the HFD mice gained ∼30 % more body weight
compared to NCD mice (p<0.001). However, RSG did not prevent
further weight again in HFD-fed mice, whereas DA significantly
Fig. 1. DA is a dual-PPAR-α/γ and PPAR-γ partial agonist. (A) DA and AA activated PPAR-γ (n = 3). (B) DA and AA activated the LBD of PPAR-γ. (C) and (D) DA
and AA docking with LBD of PPAR-γ (PDB: 6ENQ). (E) DA and AA activated PPAR-α (n = 3). (F) DA and AA activated the LBD of PPAR-α. (G) and (H) DA and AA
docking with the LBD of PPAR-α (PDB ID: 2REW) DA: Dehydroabietic acid; AA: Abietic acid; LBD: Ligand-binding domains.
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reduced the body weight of HFD-fed mice in a dose-dependent manner
(p<0.05 DA-L vs. HFD; p<0.001 DA-H vs. HFD, Fig. 5A). Fasting
blood glucose level was decreased in the HFD mice as expected
(p<0.001 vs. NCD, Fig. 5B), which was nearly normalized by RSG as
expected (Fig. 5B; F (4, 35) = 10.61, p< 0.0001; p<0.01 vs. HFD).
DA-H had a similar hypoglycemia effect as RSG (p<0.01 vs. HFD) but
DA-L not (p<0.05 vs. HFD). During OGTT, the effects of RSG and DA
on blood glucose level mirrored fasting glucose level (Fig. 5C, D; F (4,
35) = 9.875, p< 0.0001). During ITT, both doses of DA showed similar
effects as RSG to improve insulin sensitivity (Fig. 5E, F; F (4, 35) =
36.74, p< 0.0001).
Next, we identified whether DA improves IR is PPAR-γ dependent.
As shown in Sup Fig S2A (F (3, 28) = 48.64, p< 0.0001), the level of
fasted blood glucose was significantly reduced by DA treatment
(p<0.0001 vs. HFD), which was partially reversed by additional
GW9662, a selective PPAR-γ antagonist (p<0.001 DA + GW9962 vs.
DA). During OGTT and ITT, the effect of DA on blood glucose levels was
completely blocked by additional GW9962 (Sup Fig S2B, C, D and E; C:
F (3, 20) = 84.91, p< 0.0001; E:F (3, 28) = 33.02, p< 0.0001). These
data suggest that the effect of DA on glycemic control and insulin action
is PPAR-γ dependent.
3.5. DA alleviates HFD-induced hepatic steatosis and inflammation in vivo
DA also improved hepatic steatosis and dyslipidemia in vivo. As
shown in Fig. 6A–C, both gross anatomy and H&E staining showed
severe ectopic fat deposition in the liver of HFD mice reflected by
NAFLD score and ballooning (F (4, 35) = 18.4, p< 0.0001; p<0.001
vs. NCD, Table 1), in addition to increasing inflammatory score (F (4,
35) = 15.15, p< 0.0001; p<0.001 vs. NCD, Table 1), Compared with
RSG, DA had a better effect to ameliorate hepatic steatosis related
markers in a dose-dependent manner (Fig. 6A–C, Table 1; C: F (4, 35) =
70.91, p< 0.0001). As such, liver injury markers, ALT and AST were
also nearly normalized by DA treatment regardless of the dose (both
p< 0.001 vs. HFD, Fig. 6D, E; D: F (4, 40) = 15.9, p< 0.0001; E: F (4,
40) = 25.25, p< 0.0001); whereas both were further increased by RSG
treatment (p<0.05 vs. HFD, Fig. 6D, E) consistent with its side effects
in diabetic patients. DA also significantly decreased blood TG, TC and
Fig. 2. DA promotes 3T3-L1 cells differentiation in vitro. (A) representative images of 3T3-L1 cells stained with Oil Red O on day 6 of differentiation. Ins + Dex,
10 μg/mL insulin+1 μM dexamethasone. (B) Quantitative analysis of oil red O in adipocytes at 6th day of differentiation (n = 6). (C-E) Effect of DA on Glut-4,
Cyp4a10, Scd-1 mRNA expression during different days of 3T3-L1 differentiation (n = 3). *p< 0.05, **p< 0.01 and ***p< 0.001 vs. DMSO at the same day. Data
are expressed as mean± SEM, DA: Dehydroabietic acid; AA: Abietic acid; Ins: insulin; Dex: Dexamethasone.
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LDL-c levels in the HFD mice, and increased their HDL-c levels (Table 2,
F (4, 35) = 31.16, p< 0.0001), suggesting better liver lipid metabolic
profile. On the other hand, RSG nearly had no effects on these lipids
except for reducing LDL-c level, suggesting the advantage of using DA
to manage blood glucose and lipid metabolism over RSG.
In the liver, DA also activated PPAR-α and its target gene which
were reduced by HFD, including acyl-Coenzyme A dehydrogenase, C-4
to C-12 straight chain (ACADM; F (3, 28) = 111.1, p< 0.0001) and
CPT1α (F (3, 28) = 177.2; p< 0.0001) both of which are involved in β-
oxidation (Fig. 7A, B). In addition, DA, especially at a high dose, up-
regulated other genes involved in the free fatty acid breakdown and β-
oxidation (Fig. 7C). DA also dose-dependently decreased mRNA ex-
pression of inflammatory factors commonly involved in liver diseases
and injury, IL-1β (F (3, 8) = 35.23, p< 0.0001), IL-6 (F (3, 8) = 95.87,
p< 0.0001), TNF-α (F (3, 8) = 52.07, p< 0.0001), COX-1 (F (3, 8) =
45.4, p< 0.0001) and COX-2 (F (3, 8) = 39.15, p< 0.0001) (Fig. 7D).
3.6. DA activates PPAR-γ and decreases proinflammatory genes in adipose
tissue
In HFD mice, the area of white fat cells was 1.57 times bigger than
that of the NCD mice, which was only reduced by DA at a high dose
(p<0.05 DA-H vs. HFD, Fig. 8A, B; F (4, 25) = 5.691, p = 0.0021).
DA, especially at a high dose, upregulated mRNA expression of PPAR-γ,
Glut-4, Adipor, FSP27, ACOX-1, FABP4, Adiponectin (Fig. 8C). DA also
dose-dependently inhibited the expression of several inflammatory
genes (IL-1β: F (4, 10) = 93.66, p< 0.0001; IL-6: F (4, 10) = 30.72,
p< 0.0001; TNF-α: F (4, 10) = 108.5, p< 0.0001) in the white fat
(Fig. 8D), which are all associated with insulin resistance. Brown adi-
pose tissue is in charge of thermogenesis in small mammals. DA at a
high dose normalized the uncoupling protein UCP-1 protein level
(Fig. 8E, F; F (4, 25) = 4.97; p<0.01 DA-H vs. HFD,), suggesting that
heat production restored.
4. Discussion
Based on cell viability assays and binding assays, we found that DA
is more suitable than AA for clinical translation due to its higher
binding efficiency and lower toxicity (Fig. 1, Supl Fig. S1). Thus, the
biological assessments only focused on DA. The major findings in this
study are the direct evidence of DA binding to PPAR-α and PPAR-γ to
activate both pathways (Fig. 1), and confirm its mechanism of action
underlying glycemic control and lipid metabolism by using PPAR-α and
PPAR-γ antagonist in vitro (Supl Fig. S2) and in vivo (Fig. 4). The su-
periority of DA over the classical anti-diabetic medication RSG lies in its
ability to reduce blood LDL-c levels (Table 2) and hepatic steatosis
(Fig. 6), increase blood HDL-c levels (Table 2), and has liver protection.
The effect of DA to promote lipid metabolism may be mitochondrial
driven.
PPARs play an important role in metabolic disorders, therefore have
attracted significant attentions to develop/discover potent agonists.
Previous studies only reported that DA could increase mRNA expression
or activities of PPAR-γ and PPAR-α [23]; however, none showed how
DA directly connects to these two receptors. There are many pathways
to regulate PPARγ, including Axl/HSP90 [43], or ATK/mTOR [44],
SIRT1 [45]. Here, the luciferase reporter gene cloning LBD fusion
protein and molecular docking method were used to confirm that DA is
able to form hydrogen bonds with LBD-PPAR-γ and PPAR-α, rather than
non-specific bindings. These results provide evidence for suggesting
that PPAR-γ and PPAR-α are the direct targets of DA (Fig. 1). The ad-
ditional use of specific PPAR-γ and PPAR-α antagonists in vitro and in
vivo further confirmed DA’s dual-action on PPAR-γ and PPAR-α re-
sulting in effective glycemic control and lipid lowering effects in HFD-
fed mice (Supl Fig. S2, Fig. 4), respectively, which were further sup-
ported by the upregulation of the elements of the pathway for both
receptors.
DA regulates glucose metabolism in the white fat, and shares similar
mechanisms to the hypoglycemic effects of the 2nd line anti-diabetic
drug RSG. This includes upregulating Glut-4 to facilitate the uptake of
postprandial glucose surge and promoting adipocyte differentiation to
receive more glucose for long-term storage. It needs to be noted that DA
requires a higher dose than RSG to achieve similar effects on glycemic
control, due to its lower binding efficiency with PPAR-γ than that of
RSG. Nevertheless, the major discovery here is the advantage of DA
Fig. 3. DA selectively activates PPAR-γ in differentiated 3T3-L1 cells. mRNA expression of known PPAR-γ target genes (A) and adiponectin (B), ANGPTL4 (C),
Leptin (D), FGF21 (E), ANGPTL2 (F), RARRES2 (G) in differentiated 3T3-L1 cells after treated with 10 μM RSG or 10 μM DA for 24 h. Data are expressed as
mean± SEM, n = 3, DA10: dehydroabietic acid 10 μM; RSG: rosiglitazone. *p<0.05, **p< 0.01 and ***p< 0.001 vs. DMSO group; #p<0.05, ##p<0.01 and
###p<0.001 DA 10 vs. RSG group.
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over RSG, due to its ability to reduce hepatic steatosis and manage
blood cholesterol levels in obesity (Fig. 6, Table 2), in addition to its
hypoglycemic effects. The excess fat influx from the HFD can increase
circulating lipid levels leading to ectopic lipid storage in the liver
leading to steatosis. This can, in turn, lead to liver metabolic dysfunc-
tion, insulin resistance and dyslipidemia. The deposition in the arteries
can lead to the formation of atherosclerosis blocking blood supplies.
Thus, obesity is usually associated with a series of metabolic abnorm-
alities, resulting in high risks of cardiovascular and cerebrovascular
diseases [3–5]. Diabetes itself can accelerate the development of
atherosclerosis due to increasing lipid production by the liver. RSG has
been taken off the shelf in the US due to the significant cardiovascular
side effects, and advised to be used in patients without cardiovascular
conditions in other countries [11]. However, DA could improve
mitochondrial function in liver cells, while fatty acid β-oxidative is a
vital process to generate ATP from the lipids in the mitochondria. This
results in a better blood lipid profile and ameliorates hepatic lipid de-
position albeit HFD consumption ad libitum, contributing to its addi-
tional activation on PPAR-α [13,46].
Another benefit of DA used in HFD-fed mice is its weight loss effect.
PPAR-γ agonists can increase body weight due to both hypertrophy and
hyperplasia. Although DA can promote pre-adipocyte differentiation,
hypertrophy did not occur. On the contrary, fat cell size was nearly
normalized to the level of the control group albeit improved glucose
uptake ability. Increased thermogenesis reflected by an increase in
UCP-1 expression in the brown adipose tissue may mobilize the fat
storage, whereas mitochondrial β-oxidative may also increase in the
adipocytes.
Fig. 4. DA decreases lipid accumulation in
HL7702 and promotes mitochondrial
oxygen consumption via PPAR-α.
Representative images and quantifications of
nile red staining (A, C) and lipid droplets by
electron microscope (B, D) in HL7702 cells (n
= 6). (E, F) The OCR measured by seahorse
bioanalyzer in HL7702, quantification of basal
respiration, ATP production and maximal re-
spiratory capacity are shown on the graphs (n
= 6). (G) Effect of DA on mRNA expression of
metabolic markers, n = 3, *p< 0.05,
**p< 0.01 and ***p< 0.001 vs. DMSO,
#p< 0.05, ##p< 0.01 and ###p<0.001 DA vs.
DA + GW6471 group. Data are expressed as
mean± SEM. DA: Dehydroabietic acid; AA:
Abietic acid; RSG: Rosiglitazone.
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PPAR-γ agonists (RSG and thiazolidinediones) are known for their
liver toxicity which has been shown in the HFD-fed mice here, reflected
by increasing liver injury enzymes ALT and AST (Fig. 6). Therefore,
regular liver function surveillance is required to patients take thiazo-
lidinediones and RSG. DA seems to overcome such side effects, showing
liver protection in this study, reflected by reducing inflammation and
liver injury enzymes in HFD-fed mice. The anti-inflammatory effects of
DA in both white fat and liver may be still due to its activation on
PPAR-α [47,48].
High fat-induced inflammation is considered to be an important
pathological result of obesity, and is closely related to the increased risk
of various diseases, including IR and hepatic steatosis [49]. HFD in-
duced chronic inflammation, leading to excessive accumulation of fat in
various tissues, most notably in adipose tissue, as well as other insulin-
responsive organs, including the liver, which pre-disposes an individual
to the development of metabolic abnormalities. PPARγ agonists in-
hibiting NF-κB-mediated proinflammatory cytokine expression via the
PPARγ/PTEN pathways [31]. Evidence suggests that PPARα can
counter inflammation via multiple, distinct mechanisms [13], including
negatively regulates pro-inflammatory and acute phase response (APR)
signaling pathways [50,51]. Thus, dual PPAR agonists constitute pro-
mising strategies for the treatment of T2DM. PPAR also plays the key
regulatory role during the pathogenesis of inflammation induced by
HFD [47,48]. There have been some reports of DA anti-inflammatory
effects, such as DA reverses several cells response stimulated by TNF-α
in human adult dermal fibroblasts [52]. In our research, DA improved
HFD-induced inflammatory responses in liver (Fig. 7) and adipose
tissue (Fig. 8), this is consistent with the effect activation of PPAR-γ and
-α.
In conclusion, our work explored the potential therapeutic value of
the naturally occurring compound DA. Our results suggest DA is more
superior to the PPAR-γ agonist RSG for its additional beneficial effect
on blood lipid management, liver steatosis and liver functional pro-
tection, especially in the setting of long-tern HFD consumption.
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Table 1
The nonalcoholic steatohepatitis activity score.
　 NCD HFD RSG DA-L DA-H
Steatosis 0.00±0.00 2.50±0.19### 2.38±0.18 1.88± 0.23 0.88± 0.23***
Inflammation 0.13±0.13 2.00±0.27### 1.25±0.16# 1.13± 0.13* 0.75± 0.16**
Ballooning 0.25±0.16 1.88±0.13### 1.5± 0.19 0.50± 0.19*** 0.38± 0.18***
###p<0.001 vs. NCD group, *p< 0.05, **p< 0.01 and ***p< 0.001 vs. HFD group.
Table 2
DA alleviated dyslipidemia induced by high fat diet consumption in vivo.
　 NCD HFD RSG DA-L DA-H
TG 0.756± 0.0246 1.146± 0.0874## 0.963± 0.101 0.803± 0.070** 0.765± 0.0533**
TC 1.783± 0.160 4.148± 0.192### 3.708± 0.106 3.586± 0.082* 3.260± 0.170***
HDL-c 1.704± 0.086 2.368± 0.074### 2.498± 0.114 2.885± 0.152*** 3.182± 0.063***
LDL-c 0.300± 0.007 0.716± 0.046### 0.600± 0.019* 0.510± 0.018*** 0.466± 0.039***
###p<0.001 vs. NCD group, *p< 0.05, **p< 0.01 and ***p< 0.001 vs. HFD group.
Fig. 7. DA activates PPAR-α and inhibits mRNA expression of inflammatory factors in the liver. (A) representative immunohistochemistry staining of PPAR-α,
ACADM, CPT1α in the liver. (B) Quantification of the immunohistochemistry staining, n = 6. (C) mRNA expression of known PPAR-α signaling genes in the liver. (D)
mRNA expression of inflammatory cytokines. Data are expressed as mean± SEM, n = 3, *p<0.05, **p<0.01 and ***p<0.001. DA-H: high dose of Dehydroabietic
acid (20 mg/kg/d); DA-L: low dose of Dehydroabietic acid (10 mg/kg/d); RSG: Rosiglitazone (4 mg/kg/d).
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